A report from J.P. Morgan reiterates its Overweight rating on Covidien COV.
The report states, “Covidien reported fiscal 4Q results this morning, with sales of $3.078B (+15.3%, +3.0% organic by our math) coming in $44M above Street consensus and $36M above our forecast. Sales included a well-advertised extra selling week, which we estimate added around $195M (730bps) to revenues in the quarter.”
COV closed yesterday at $47.31.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in